Silence Therapeutics plc (SLNCF)

Market Cap	168.12M
Revenue (ttm)	27.70M
Net Income (ttm)	-71.53M
Shares Out	n/a
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,000
Average Volume	466
Open	0.8000
Previous Close	0.9700
Day's Range	0.8000 - 0.9700
52-Week Range	0.4986 - 14.7500
Beta	1.19
RSI	48.60
Earnings Date	May 15, 2025

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, includin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 116
• Stock Exchange: OTCMKTS
• Ticker Symbol: SLNCF

Financial Performance

In 2024, Silence Therapeutics's revenue was $43.26 million, an increase of 36.71% compared to the previous year's $31.64 million. Losses were -$45.31 million, -16.45% less than in 2023.